GleamWall
中文EN

ALLR Allarity Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1860657 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.7%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,938.3%
Net margin-4,493.7%
FCF margin-3,785.4%
EBITDA margin—

Returns

ROE-322.7%
ROA-65.5%
ROIC (approx.)—
Asset turnover0.01x

Leverage & solvency

Liabilities / assets108.3%
Debt / equity—
Current ratio0.91x
Interest coverage-6.83x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-10.6%
Payout ratio—
Capex / revenue20.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$5,000$0$25,000$320,000$0$0$0—
R&D expense$4.22M$1.34M$1.30M$1.67M$1.20M$2.32M$1.40M$1.85M
SG&A expense$1.29M$1.33M$1.42M$1.56M$1.31M$1.81M$1.63M$5.47M
Operating income-$5.51M-$2.67M-$2.69M-$2.92M-$2.52M-$4.13M-$3.04M-$7.32M
Interest expense$1.01M$719,000$229,000$59,000$57,000$12,000$57,000$75,000
Pretax income———-$3.37M-$2.81M-$2.32M-$2.73M-$7.45M
Income tax———$0$0$0$0$0
Net income-$6.20M-$3.40M-$2.75M-$3.37M-$2.81M-$2.32M-$2.73M-$7.45M
EBITDA—————-$4.12M-$3.02M-$7.32M
EPS (basic)-0.39-0.21-0.17—-0.19-0.15-0.25—
EPS (diluted)————————
Balance sheet
Cash & equivalents$14.09M$16.98M$19.81M$14.69M$16.89M$17.80M$25.20M$19.53M
Current assets$26.87M$31.73M$34.50M$17.93M$20.47M$20.88M$29.42M$22.34M
PP&E, net$354,000$386,000$420,000$330,000$330,000$322,000$308,000$309,000
Intangibles———————$0
Total assets$27.22M$32.12M$34.92M$18.26M$20.80M$21.20M$29.73M$22.65M
Current liabilities$29.48M$28.58M$28.00M$8.43M$8.79M$9.04M$11.06M$10.84M
Short-term debt$21.58M$20.86M$20.08M$0————
Total liabilities$29.48M$28.58M$28.00M$8.43M$8.79M$9.04M$11.06M$10.84M
Shareholders' equity-$2.26M$3.54M$6.92M$9.83M$12.01M$12.17M$18.67M$11.81M
Shares outstanding16.15M15.91M15.82M16.08M16.11M14.62M17.02M7.30M
Cash flow statement
Operating cash flow-$2.88M-$2.56M-$4.49M-$3.24M-$3.41M-$5.48M-$2.69M-$3.21M
Capital expenditure$0$0$64,000$8,000$0$0$0—
Free cash flow-$2.88M-$2.56M-$4.56M-$3.25M-$3.41M-$5.48M-$2.69M—
Investing cash flow$0$0-$64,000-$8,000$0$0$0—
Financing cash flow$0$0$19.74M-$240,000$2.31M-$2.56M$11.14M$4.24M
Depreciation & amortization—————$12,000$11,000$1,000
Stock-based compensation$191,000$188,000$160,000$47,000$132,000$164,000$139,000$64,000
Share buybacks$0$0$262,000$484,000$141,000$2.56M$0$0

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.